Aditum Bio
Overview
Aditum Bio is a biotech venture capital firm dedicated to translating scientific discoveries into innovative medicines. Founded in 2019 by former Novartis CEO Joe Jimenez and former President of the Novartis Institutes for BioMedical Research, Dr. Mark Fishman, the firm operates with a mission to provide patients access to medicines that might not otherwise be developed. Aditum Bio's unique model combines scientific expertise with operational capabilities to accelerate drug development, enabling rapid company formation and execution to bring therapies to patients faster. The firm's investment strategy focuses on in-licensing promising drug candidates targeting fundamental disease mechanisms and spinning out individual companies to advance these candidates through Phase II clinical trials. Aditum Bio's portfolio includes companies like Versanis Bio, formed in 2021 to develop bimagrumab for metabolic diseases and obesity, and Vitalli Bio, established in 2023 to develop therapies for immunological disorders. The firm emphasizes a patient-centric, collaborative, curious, and courageous approach to addressing significant unmet medical needs. Aditum Bio's track record demonstrates its commitment to improving public health by accelerating R&D in disease areas with large and targeted patient populations. By leveraging data, software, and technology, the firm aims to bring innovative medicines through the clinical trial phase more quickly and cost-effectively than traditional pharmaceutical companies. This approach has led to the formation of multiple portfolio companies, each dedicated to advancing specific therapeutic areas, thereby contributing to the broader goal of enhancing health outcomes across diverse medical fields.
Investment Focus
- In-licensing of promising drug candidates
- Focus on fundamental disease mechanisms
- Advancement through Phase II clinical trials
Portfolio Companies
Reach Aditum Bio directly
Verified work email, phone and LinkedIn for the full team — one spreadsheet, one payment, yours to keep.
Unlock full contacts →Frequently asked questions about Aditum Bio
What sectors does Aditum Bio invest in?
Aditum Bio invests in Healthcare, Pharmaceuticals and Biotechnology, and is based in Oakland, United States. Aditum Bio is listed as a corporate vc in the ConnectSafely investor database.
What stage does Aditum Bio invest at?
Aditum Bio backs companies at Seed, Early Stage, Series A, Series B, Growth and Late Stage, writing cheques of 5M - 50M.
Which regions does Aditum Bio invest in?
Aditum Bio invests across United States.
Who are the partners at Aditum Bio?
Team members listed for Aditum Bio include Joe Jimenez (Co-Founder and Managing Director) and David Pugatch (Vice President Clinical Development).
What companies has Aditum Bio invested in?
Aditum Bio's portfolio includes Versanis Bio and Vitalli Bio.
How do I contact Aditum Bio?
Aditum Bio's contact details — including phone and LinkedIn — are listed in the ConnectSafely investor database, along with its website and the LinkedIn profiles of its partners.
Last updated · Source: ConnectSafely investor database
